Premia Global Advisors LLC Invests $264,000 in Novartis AG (NVS) Stock
Premia Global Advisors LLC bought a new position in shares of Novartis AG (NYSE:NVS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,163 shares of the company’s stock, valued at approximately $264,000.
Other institutional investors have also recently bought and sold shares of the company. Wealthcare Advisory Partners LLC bought a new stake in Novartis during the 3rd quarter worth approximately $106,000. Pinnacle Wealth Planning Services Inc. bought a new stake in Novartis during the 4th quarter worth approximately $113,000. Calton & Associates Inc. bought a new stake in Novartis during the 4th quarter worth approximately $118,000. SeaCrest Wealth Management LLC bought a new position in shares of Novartis in the 4th quarter worth $124,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Novartis in the 4th quarter worth $178,000. 10.80% of the stock is currently owned by institutional investors and hedge funds.
Novartis AG (NYSE NVS) opened at $82.91 on Tuesday. The company has a market cap of $191,792.67, a price-to-earnings ratio of 25.51, a PEG ratio of 1.92 and a beta of 0.78. Novartis AG has a twelve month low of $72.67 and a twelve month high of $94.19. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31.
A number of equities analysts have recently commented on NVS shares. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $87.51.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/premia-global-advisors-llc-invests-264000-in-novartis-ag-nvs-stock/1927722.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.